Deutetrabenazine(DTBZ)is a selective oral small molecule inhibitor of vesicular monoamine transporter 2(VMAT2).Its pharmacological action works by inhibiting VMAT2,thereby reducing the release of presynaptic dopamine and alleviating tardive dyskinesia symptoms caused by long-term use of dopamine receptor antagonists.Compared with tetrabenazine,DTBZ has longer half-life,lower peak plasma concentration,and smaller plasma concentration fluctuations.Clinical studies demonstrate that DTBZ significantly improves abnormal involuntary movement in patients with tardive dyskinesia and has a favourable safety profile.Based on available clinical evidence and practical experience,this paper discuss the common questions about DTBZ including the suitable population,dose,duration of treatment,combination administration with antipsychotics,efficacy assessment and application in special populations.This article aimed to provide guidance and recommendations on clinical application of DTBZ for clinicians.

In recent years,the potential role of mitochondrial dynamics imbalance in the pathogenesis of various psychiatric disorders has attracted growing attention.Mitochondria regulate energy metabolism,oxidative stress,apoptosis,and neuronal function through dynamic processes such as fission and fusion.Disruption of these processes may impair synaptic function and neural network stability.In schizophrenia,depression,bipolar disorder,Alzheimer disease,and autism spectrum disorders,studies have reported dysregulated expression of mitochondrial fission-related proteins DRP1 and FIS1,as well as fusion-related proteins MFN1,MFN2,and OPA1,accompanied by structural and functional mitochondrial impairments,neuronal apoptosis,and synaptic loss.Evidence from clinical studies,animal models,and cell experiments further supports that these mitochondrial dynamics abnormalities are closely associated with cognitive deficits,emotional disturbances,and neurodegenerative changes.Although mitochondrial dynamic dysfunction alone cannot fully explain the onset of psychiatric disorders,it may represent a potential biological mechanism that offers new insights into disease mechanisms and provide a theoretical basis for developing targeted intervention strategies.

Blonanserin,a second-generation atypical antipsychotic agent,acts as an antagonist for dopamine D2,D3,and serotonin 5-HT2A receptors.Clinical studies have demonstrated that blonanserin is non-inferior to other antipsychotics,such as haloperidol and risperidone,in alleviating the symptoms of schizophrenia.Moreover,it exhib-its beneficial effects on cognitive symptoms and social functioning,with a favorable safety profile,making it one of the key treatment options for schizophrenia.With extensive clinical experience accumulated in China,this expert consensus aims to provide psychiatrists with updated and localized guidance on the optimal use of blonan-serin.Based on a systematic review of the latest evidence-particularly studies in Chinese population,this paper pres-ents the updated Chinese expert recommendations for the clinical use of blonanserin in 2024.

Objective:To explore the relationship between impulsivity traits,anxiety,and symptoms of eating disorders,with a focus on the mediating effect of anxiety between impulsivity and eating disorder symptoms.Me-thods:A total of 244 patients with eating disorders meeting the DSM-5 diagnostic criteria for anorexia nervosa(AN)and bulimia nervosa(BN)were enrolled,and the Eating Disorder Inventory-1(EDI-1),Barratt Impulsive-ness Scale(BIS-11),and the State Anxiety Inventory(SAI)were assessed.Mediation role analysis was performed by SPSS macro PROCESS program.Results:There was a significant positive correlation between the total score of BIS-11,SAI and EDI-1 in AN and BN patients(AN,r=0.56,0.63,0.72;P＜0.001.BN,r=0.51,0.31,0.56;P＜0.001 or P＜0.01).The total score of SAI played a mediating effect between the total score of BIS-11 and the total score of EDI-1,but the total score of SAI played a partial mediating effect(effect ratio was 46.9％)in patients with AN,and the total score of SAI played a full mediating effect in patients with BN.Conclusion:Impulsive trait and anxiety may be positive predictors of eating disorder symptoms.Anxiety mediates the relationship between impul-sivity trait and eating disorder symptoms,with a partial mediating effect in patients with AN and a full mediating effect in patients with BN.

Objective To investigate the impact of chronic observational social defeat stress on multidimensional behaviors in female mice,including social interaction,emotion,and cognition,as well as the underlying molecular mechanisms.Methods Adult female C57BL6N mice were divided into a stress group and a control group.Behavioral assessment were conducted through social interaction tests,anxiety-like behavior tests,and cognitive tests(novel object recognition and spatial memory).Synaptic plasticity-related proteins in the hippocampus were detected using Western blot.Results Behavioral tests revealed that the stress group showed reduced social interaction time compared to the control group[(106.2±9.31)s vs.(156.5±14.81)s,P<0.05].In a novel environment,the stress group consumed less food than the control group[(0.10±0.01)g vs.(0.16±0.02)g,P<0.05].Cognitive tests demonstrated that the stress group exhibited impaired novel object recognition[(52.17%%±2.67%)vs.(65.91%±5.23%)]and spatial memory[(61.84%±3.14%)vs.(74.13%±1.94%)]compared to the control group(P<0.05).Western blot analysis showed that the expression of hippocampal synaptic plasticity-related proteins,including the glutamate ionotropic receptor N-methyl-D-aspartate(NMDA)receptor subunit NR2A[(0.66±0.05)vs.(0.89±0.08)]and brain-derived neurotrophic factor(BDNF)[(0.81±0.05)vs.(1.14±0.06)],was significantly decreased in the stress group(P<0.05).Conclusion Chronic observational social defeat stress induces social withdrawal,anxiety-like behaviors,and cognitive deficits in female mice.These effects may be associated with reduced expression of NR2A and BDNF in the hippocampus.

Schizophrenia is a severe mental disorder prioritized in psychiatric prevention and treatment with a global prevalence rate of approximately 1%. It typically onsets during adolescence and early adulthood with a chronic disease course, leading to a heavy burden on patients, families, and society. The etiology and pathological mechanisms of schizophrenia remain incompletely clarified. Current treatment strategies primarily rely on symptomatic pharmacological therapy. Delayed seeking help, long duration of untreated psychosis, insufficient treatment efficacy, adverse drug reactions, and poor treatment compliance are still challenges in the treatment of schizophrenia. Current research hotpots focus on uncovering the pathological mechanisms of the disease, exploring objective prediction indicators for early diagnosis and personalized treatment, and developing more effective treatment strategies. This article reviews significant research progress over the past decade in pathogenesis, clinical diagnosis, and development of treatment approaches for schizophrenia. It proposes future development directions to provide valuable insights for professionals in standardizing diagnosis and treatment and future research directions.

Major depressive disorder is a prevalent and debilitating mental disorder worldwide. Suicidal ideation and behavior represent a severe clinical manifestation closely associated with high mortality and disease burden. Current antidepressants have a delayed onset of action and fail to address the urgent need for rapid symptom relief in patients with major depressive disorder with suicidal ideation or behavior (MDSI). The glutamatergic antidepressant esketamine has demonstrated rapid antidepressant efficacy and a tolerable safety profile in patients with MDSI in multiple clinical trials, making it a promising therapeutic option. Esketamine is a non-selective, non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist. In 2023, the nasal spray formulation was approved in China for use in combination with oral antidepressants to alleviate depressive symptoms in adults with MDSI. This review summarizes the latest clinical research progress on esketamine nasal spray for MDSI, providing evidence-based guidance for psychiatrists in clinical decision-making.

Off-label drug use in psychiatry has long been prevelent, with common clinical practices lacking standardized guidance and associated risks warranting close attention. To address the practical needs of frontline clinicians, the Mental Health Branch of the China National Narcotic Drugs Association, in collaboration with multiple institutions, has launched a project to formulate the Guidelines on Off-label Use of Common Psychiatric Medications in China ("Guideline"). The Guidelines focuses on evaluating evidence and formulating recommendations regarding off-label use scenarios of common psychiatric medications, including indications, dosage, administration, and specific populations. It employs standard methodological frameworks, notably the GRADE-ADOLOPMENT approach (Grading of Recommendations Assessment, Development, and Evaluation Evidence to Decision frameworks for adoption, adaptation, and de?novo development of recommendations), to ensure both scientific rigor and practical applicability. This proposal systematically outlines the background, objectives, processes, organizational structure, and methodologies of the Guideline, aiming to provide psychiatrists with practical and evidence-based prescribing recommendations.

Objective:To explore the relationship between impulsivity traits,anxiety,and symptoms of eating disorders,with a focus on the mediating effect of anxiety between impulsivity and eating disorder symptoms.Me-thods:A total of 244 patients with eating disorders meeting the DSM-5 diagnostic criteria for anorexia nervosa(AN)and bulimia nervosa(BN)were enrolled,and the Eating Disorder Inventory-1(EDI-1),Barratt Impulsive-ness Scale(BIS-11),and the State Anxiety Inventory(SAI)were assessed.Mediation role analysis was performed by SPSS macro PROCESS program.Results:There was a significant positive correlation between the total score of BIS-11,SAI and EDI-1 in AN and BN patients(AN,r=0.56,0.63,0.72;P＜0.001.BN,r=0.51,0.31,0.56;P＜0.001 or P＜0.01).The total score of SAI played a mediating effect between the total score of BIS-11 and the total score of EDI-1,but the total score of SAI played a partial mediating effect(effect ratio was 46.9％)in patients with AN,and the total score of SAI played a full mediating effect in patients with BN.Conclusion:Impulsive trait and anxiety may be positive predictors of eating disorder symptoms.Anxiety mediates the relationship between impul-sivity trait and eating disorder symptoms,with a partial mediating effect in patients with AN and a full mediating effect in patients with BN.

Blonanserin,a second-generation atypical antipsychotic agent,acts as an antagonist for dopamine D2,D3,and serotonin 5-HT2A receptors.Clinical studies have demonstrated that blonanserin is non-inferior to other antipsychotics,such as haloperidol and risperidone,in alleviating the symptoms of schizophrenia.Moreover,it exhib-its beneficial effects on cognitive symptoms and social functioning,with a favorable safety profile,making it one of the key treatment options for schizophrenia.With extensive clinical experience accumulated in China,this expert consensus aims to provide psychiatrists with updated and localized guidance on the optimal use of blonan-serin.Based on a systematic review of the latest evidence-particularly studies in Chinese population,this paper pres-ents the updated Chinese expert recommendations for the clinical use of blonanserin in 2024.